{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T04:23:34Z","timestamp":1772684614955,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.medcli.2022.06.017","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T03:52:21Z","timestamp":1662436341000},"page":"388-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Esteatohepatitis no alcoh\u00f3lica"],"prefix":"10.1016","volume":"159","author":[{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.06.017_bib0305","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"May Clin Proc"},{"key":"10.1016\/j.medcli.2022.06.017_bib0310","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0315","first-page":"161","article-title":"Looking for a new name for non-alcoholic fatty liver disease in Spanish: Esteatosis hep\u00e1tica metab\u00f3lica (EHmet)","volume":"113","author":"Romero-G\u00f3mez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.medcli.2022.06.017_bib0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MEG.0b013e32832fcdf0","article-title":"Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain","volume":"22","author":"Caballer\u00eda","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0325","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0330","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","article-title":"Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease","volume":"76","author":"Guo","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0335","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0340","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: A multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0345","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0350","doi-asserted-by":"crossref","first-page":"102336","DOI":"10.1016\/j.ceca.2020.102336","article-title":"Role of mitochondria in liver metabolic health and diseases","volume":"94","author":"Morio","year":"2021","journal-title":"Cell Calcium"},{"key":"10.1016\/j.medcli.2022.06.017_bib0355","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties","volume":"46","year":"1998","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0360","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep4.1710","article-title":"Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"5","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.medcli.2022.06.017_bib0365","doi-asserted-by":"crossref","first-page":"585425","DOI":"10.3389\/fmed.2020.585425","article-title":"Psychological biomarkers and fibrosis: An innovative approach to nonalcoholic fatty liver disease","volume":"7","author":"Funuyet-Salas","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.medcli.2022.06.017_bib0370","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0375","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0380","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0385","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2022.06.017_bib0390","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of Hepamet Fibrosis Scoring System-A simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-021-01652-8","article-title":"Non-invasive biomarkers of nonalcoholic steatohepatitis: The FNIH NIMBLE project","volume":"28","author":"Sanyal","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.medcli.2022.06.017_bib0400","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.medcli.2022.06.017_bib0405","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: A cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0410","article-title":"AEEH \u00abConsensus about detection and referral of hidden prevalent liver diseases\u00bb","author":"Romero-G\u00f3mez","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0415","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.15116","article-title":"Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease","volume":"42","author":"Mendoza","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2022.06.017_bib0420","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0425","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.15323","article-title":"Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology","volume":"42","author":"Calleja","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2022.06.017_bib0430","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0435","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejrad.2017.05.028","article-title":"Liver MRI: From basic protocol to advanced techniques","volume":"93","author":"Donato","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0440","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/mrm.21301","article-title":"Fat quantification with IDEAL gradient echo imaging: Correction of bias from T1 and noise","volume":"58","author":"Liu","year":"2007","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0445","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jmri.22701","article-title":"Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms","volume":"34","author":"Kang","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.medcli.2022.06.017_bib0450","doi-asserted-by":"crossref","first-page":"31421","DOI":"10.1038\/srep31421","article-title":"Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease","volume":"6","author":"Gallego-Dur\u00e1n","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2022.06.017_bib0455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0460","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0465","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0470","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0475","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0485","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of>10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2022.06.017_bib0490","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0495","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2022.06.017_bib0500","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/nu11030677","article-title":"Impact of nutritional changes on nonalcoholic fatty liver disease","volume":"11","author":"Perdomo","year":"2019","journal-title":"Nutrients."},{"key":"10.1016\/j.medcli.2022.06.017_bib0505","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3748\/wjg.15.1809","article-title":"Olive oil consumption and non-alcoholic fatty liver disease","volume":"15","author":"Assy","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0510","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3945\/ajcn.2009.29096","article-title":"Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: The RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial","volume":"92","author":"Jebb","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.medcli.2022.06.017_bib0515","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3945\/ajcn.114.086314","article-title":"Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: A systematic review and meta-analysis","volume":"100","author":"Chung","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2022.06.017_bib0520","first-page":"71A","article-title":"Low hypocaloric Mediterranean diet versus standard diet in biopsy proven NAFLD patients","volume":"74","author":"Martin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0525","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.3389\/fnut.2021.709683","article-title":"Effect of intermittent fasting on non-alcoholic fatty liver disease: Systematic review and meta-analysis","volume":"8","author":"Yin","year":"2021","journal-title":"Front Nutr"},{"key":"10.1016\/j.medcli.2022.06.017_bib0530","article-title":"Dietary recommendations in the management of NAFLD: A Nutritional Geometry perspective","author":"Romero-G\u00f3mez","year":"2022","journal-title":"Sem Liver Dis"},{"key":"10.1016\/j.medcli.2022.06.017_bib0535","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0540","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0545","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR\u00a0trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0550","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0555","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and\u00a0-\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2022.06.017_bib0560","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2022.06.017_bib0565","article-title":"Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease","author":"Zou","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0570","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2022.06.017_bib0575","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.06.017_bib0580","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0585","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.06.017_bib0590","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0595","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2022.06.017_bib0600","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jhepr.2020.100148","article-title":"Stratification of patients in NASH clinical trials: A pitfall for trial success","volume":"2","author":"Ampuero","year":"2020","journal-title":"JHEP Rep"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322004031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322004031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:55:06Z","timestamp":1758419706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322004031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0025775322004031"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.06.017","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esteatohepatitis no alcoh\u00f3lica","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}